News

The American Cancer Society awarded Hollings researcher David Long, Ph.D., a Catalyst grant to study how two proteins' interaction affects genomic instability.

Not enough people are aware of lung cancer screening, even though the test can find early-stage, treatable cancer, Hollings researchers find.

Quitting smoking soon after a cancer diagnosis adds an average of two years to a patient's life, a new study finds.

A new study from MUSC Hollings Cancer Center shows how a receptor called PPAR δ helps disable the immune system so that T-cells can’t kill cancer cells.

Models help scientists understand how cancer develops - but researchers haven't had one for most ovarian cancers.

MUSC Hollings researchers find that targeting an immunosuppressive protein on two fronts can reduce metastasis and restore sensitivity to immunotherapy.

MUSC scientists report successful Alaskan expedition for novel therapeutics for pancreatic cancer.

A newly approved targeted therapy for small cell lung cancer is at the forefront of a new type of drug for solid tumors.

Hollings was part of an international clinical trial that led to the FDA approval of a new drug to treat certain types of gliomas.

Two Hollings researchers are working together to develop a new way to get depression treatment to people with likely incurable cancer.